MovDisordV3, Main, Exploration, bibRecord, 004032

Multiple system atrophy: An update

Identifieur interne : 004032 ( Main/Exploration ); précédent : 004031; suivant : 004033

Multiple system atrophy: An update

Auteurs : Gregor K. Wenning [Autriche] ; Felix Geser [Autriche] ; Michaela Stampfer-Kountchev [Autriche] ; François Tison [Autriche]

Source :

Movement Disorders [ 0885-3185 ] ; 2003-09.

RBID : ISTEX:E4A65AD7BF3DD5CB1D2BDC0A82AF58121D1F120F

Descripteurs français

Pascal (Inist)
- Anatomopathologie, Article synthèse, Atrophie multisystématisée, Benzothiazole, Exploration, Homme, Névroglie, Riluzole, Symptomatologie, Traitement.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Anatomic pathology, Animals, Benzothiazole, Brain (drug effects), Brain (pathology), Clinical Trials as Topic, Exploration, Human, Humans, Inclusion Bodies (drug effects), Inclusion Bodies (pathology), Levodopa (therapeutic use), Multiple System Atrophy (diagnosis), Multiple System Atrophy (drug therapy), Multiple System Atrophy (pathology), Multiple system atrophy, Nerve Tissue Proteins (metabolism), Neuroglia, Neurologic Examination (drug effects), Neurons (drug effects), Neurons (pathology), Neuroprotective Agents (therapeutic use), Parkinsonian Disorders (diagnosis), Parkinsonian Disorders (drug therapy), Parkinsonian Disorders (pathology), Review, Riluzole, Symptomatology, Synucleins, Treatment, alpha-Synuclein, glia, multiple system atrophy, riluzole, treatment.
MESH :
- chemical , metabolism : Nerve Tissue Proteins.
- chemical , therapeutic use : Levodopa, Neuroprotective Agents.
- diagnosis : Multiple System Atrophy, Parkinsonian Disorders.
- drug effects : Brain, Inclusion Bodies, Neurologic Examination, Neurons.
- drug therapy : Multiple System Atrophy, Parkinsonian Disorders.
- pathology : Brain, Inclusion Bodies, Multiple System Atrophy, Neurons, Parkinsonian Disorders.
- Animals, Clinical Trials as Topic, Humans, Synucleins, alpha-Synuclein.

Abstract

Multiple system atrophy (MSA) is a sporadic neurodegenerative disorder that usually manifests in the early sixth decade of life and progresses relentlessly with a mean survival of 9 years. Clinically, MSA is dominated by autonomic/urogenital failure, which may be associated with either levodopa (L‐dopa) ‐unresponsive parkinsonism in 80% of cases (MSA‐P subtype) or with cerebellar ataxia in 20% of cases (MSA‐C subtype). Pathologically, MSA is characterized by a neuronal multisystem degeneration and abnormal glial cytoplasmic inclusions containing α‐synuclein aggregates. Pharmacological treatment of motor features is disappointing except for a transient L‐dopa response in a minority of MSA‐P patients. In contrast, autonomic and urogenital features of MSA should be identified early on, because they can be treated effectively in many instances. Neuroprotective strategies are presently unavailable, however, two multicentre European trials have been launched to evaluate the effects of riluzole and human recombinant growth hormone on disease progression in MSA. Clearly, further randomised, controlled trials are required to identify effective symptomatic or neuroprotective agents in MSA. Several in vivo models have become available to allow a careful preselection of candidate agents. Several research groups have been formed in Europe (EMSA‐SG, NNIPPS) and United States (NAMSA‐SG), providing a framework for coordinated trial activity in MSA. © 2003 Movement Disorder Society

Url:

https://api.istex.fr/document/E4A65AD7BF3DD5CB1D2BDC0A82AF58121D1F120F/fulltext/pdf

DOI: 10.1002/mds.10561

Affiliations:

Autriche

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Multiple system atrophy: An update</title>
<author><name sortKey="Wenning, Gregor K" sort="Wenning, Gregor K" uniqKey="Wenning G" first="Gregor K." last="Wenning">Gregor K. Wenning</name>
</author>
<author><name sortKey="Geser, Felix" sort="Geser, Felix" uniqKey="Geser F" first="Felix" last="Geser">Felix Geser</name>
</author>
<author><name sortKey="Stampfer Ountchev, Michaela" sort="Stampfer Ountchev, Michaela" uniqKey="Stampfer Ountchev M" first="Michaela" last="Stampfer-Kountchev">Michaela Stampfer-Kountchev</name>
</author>
<author><name sortKey="Tison, Francois" sort="Tison, Francois" uniqKey="Tison F" first="François" last="Tison">François Tison</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:E4A65AD7BF3DD5CB1D2BDC0A82AF58121D1F120F</idno>
<date when="2003" year="2003">2003</date>
<idno type="doi">10.1002/mds.10561</idno>
<idno type="url">https://api.istex.fr/document/E4A65AD7BF3DD5CB1D2BDC0A82AF58121D1F120F/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000504</idno>
<idno type="wicri:Area/Istex/Curation">000504</idno>
<idno type="wicri:Area/Istex/Checkpoint">002962</idno>
<idno type="wicri:doubleKey">0885-3185:2003:Wenning G:multiple:system:atrophy</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:14502654</idno>
<idno type="wicri:Area/PubMed/Corpus">003714</idno>
<idno type="wicri:Area/PubMed/Curation">003714</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003724</idno>
<idno type="wicri:Area/Ncbi/Merge">000B50</idno>
<idno type="wicri:Area/Ncbi/Curation">000B50</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000B50</idno>
<idno type="wicri:doubleKey">0885-3185:2003:Wenning G:multiple:system:atrophy</idno>
<idno type="wicri:Area/Main/Merge">005C55</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:04-0080432</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002385</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000936</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002399</idno>
<idno type="wicri:doubleKey">0885-3185:2003:Wenning G:multiple:system:atrophy</idno>
<idno type="wicri:Area/Main/Merge">005F45</idno>
<idno type="wicri:Area/Main/Curation">004032</idno>
<idno type="wicri:Area/Main/Exploration">004032</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Multiple system atrophy: An update</title>
<author><name sortKey="Wenning, Gregor K" sort="Wenning, Gregor K" uniqKey="Wenning G" first="Gregor K." last="Wenning">Gregor K. Wenning</name>
<affiliation wicri:level="1"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, University Hospital, Innsbruck</wicri:regionArea>
<wicri:noRegion>Innsbruck</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Geser, Felix" sort="Geser, Felix" uniqKey="Geser F" first="Felix" last="Geser">Felix Geser</name>
<affiliation wicri:level="1"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, University Hospital, Innsbruck</wicri:regionArea>
<wicri:noRegion>Innsbruck</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Stampfer Ountchev, Michaela" sort="Stampfer Ountchev, Michaela" uniqKey="Stampfer Ountchev M" first="Michaela" last="Stampfer-Kountchev">Michaela Stampfer-Kountchev</name>
<affiliation wicri:level="1"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, University Hospital, Innsbruck</wicri:regionArea>
<wicri:noRegion>Innsbruck</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Tison, Francois" sort="Tison, Francois" uniqKey="Tison F" first="François" last="Tison">François Tison</name>
<affiliation wicri:level="1"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, University Hospital, Innsbruck</wicri:regionArea>
<wicri:noRegion>Innsbruck</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2003-09">2003-09</date>
<biblScope unit="vol">18</biblScope>
<biblScope unit="issue">S6</biblScope>
<biblScope unit="supplement">6</biblScope>
<biblScope unit="page" from="34">34</biblScope>
<biblScope unit="page" to="42">42</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">E4A65AD7BF3DD5CB1D2BDC0A82AF58121D1F120F</idno>
<idno type="DOI">10.1002/mds.10561</idno>
<idno type="ArticleID">MDS10561</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anatomic pathology</term>
<term>Animals</term>
<term>Benzothiazole</term>
<term>Brain (drug effects)</term>
<term>Brain (pathology)</term>
<term>Clinical Trials as Topic</term>
<term>Exploration</term>
<term>Human</term>
<term>Humans</term>
<term>Inclusion Bodies (drug effects)</term>
<term>Inclusion Bodies (pathology)</term>
<term>Levodopa (therapeutic use)</term>
<term>Multiple System Atrophy (diagnosis)</term>
<term>Multiple System Atrophy (drug therapy)</term>
<term>Multiple System Atrophy (pathology)</term>
<term>Multiple system atrophy</term>
<term>Nerve Tissue Proteins (metabolism)</term>
<term>Neuroglia</term>
<term>Neurologic Examination (drug effects)</term>
<term>Neurons (drug effects)</term>
<term>Neurons (pathology)</term>
<term>Neuroprotective Agents (therapeutic use)</term>
<term>Parkinsonian Disorders (diagnosis)</term>
<term>Parkinsonian Disorders (drug therapy)</term>
<term>Parkinsonian Disorders (pathology)</term>
<term>Review</term>
<term>Riluzole</term>
<term>Symptomatology</term>
<term>Synucleins</term>
<term>Treatment</term>
<term>alpha-Synuclein</term>
<term>glia</term>
<term>multiple system atrophy</term>
<term>riluzole</term>
<term>treatment</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Nerve Tissue Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Levodopa</term>
<term>Neuroprotective Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Multiple System Atrophy</term>
<term>Parkinsonian Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Brain</term>
<term>Inclusion Bodies</term>
<term>Neurologic Examination</term>
<term>Neurons</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Multiple System Atrophy</term>
<term>Parkinsonian Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Brain</term>
<term>Inclusion Bodies</term>
<term>Multiple System Atrophy</term>
<term>Neurons</term>
<term>Parkinsonian Disorders</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Clinical Trials as Topic</term>
<term>Humans</term>
<term>Synucleins</term>
<term>alpha-Synuclein</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Anatomopathologie</term>
<term>Article synthèse</term>
<term>Atrophie multisystématisée</term>
<term>Benzothiazole</term>
<term>Exploration</term>
<term>Homme</term>
<term>Névroglie</term>
<term>Riluzole</term>
<term>Symptomatologie</term>
<term>Traitement</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Multiple system atrophy (MSA) is a sporadic neurodegenerative disorder that usually manifests in the early sixth decade of life and progresses relentlessly with a mean survival of 9 years. Clinically, MSA is dominated by autonomic/urogenital failure, which may be associated with either levodopa (L‐dopa) ‐unresponsive parkinsonism in 80% of cases (MSA‐P subtype) or with cerebellar ataxia in 20% of cases (MSA‐C subtype). Pathologically, MSA is characterized by a neuronal multisystem degeneration and abnormal glial cytoplasmic inclusions containing α‐synuclein aggregates. Pharmacological treatment of motor features is disappointing except for a transient L‐dopa response in a minority of MSA‐P patients. In contrast, autonomic and urogenital features of MSA should be identified early on, because they can be treated effectively in many instances. Neuroprotective strategies are presently unavailable, however, two multicentre European trials have been launched to evaluate the effects of riluzole and human recombinant growth hormone on disease progression in MSA. Clearly, further randomised, controlled trials are required to identify effective symptomatic or neuroprotective agents in MSA. Several in vivo models have become available to allow a careful preselection of candidate agents. Several research groups have been formed in Europe (EMSA‐SG, NNIPPS) and United States (NAMSA‐SG), providing a framework for coordinated trial activity in MSA. © 2003 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Autriche</li>
</country>
</list>
<tree><country name="Autriche"><noRegion><name sortKey="Wenning, Gregor K" sort="Wenning, Gregor K" uniqKey="Wenning G" first="Gregor K." last="Wenning">Gregor K. Wenning</name>
</noRegion>
<name sortKey="Geser, Felix" sort="Geser, Felix" uniqKey="Geser F" first="Felix" last="Geser">Felix Geser</name>
<name sortKey="Stampfer Ountchev, Michaela" sort="Stampfer Ountchev, Michaela" uniqKey="Stampfer Ountchev M" first="Michaela" last="Stampfer-Kountchev">Michaela Stampfer-Kountchev</name>
<name sortKey="Tison, Francois" sort="Tison, Francois" uniqKey="Tison F" first="François" last="Tison">François Tison</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004032 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004032 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:E4A65AD7BF3DD5CB1D2BDC0A82AF58121D1F120F
   |texte=   Multiple system atrophy: An update
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Multiple system atrophy: An update

Multiple system atrophy: An update

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.